ArticleMovement disorders : official journal of the Movement Disorder Society2026
Progression of Motor and Cognitive Functions in Isolated REM Sleep Behavior Disorder: A 7-Year Prospective Matched Cohort Study.
Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundAlthough clinical markers (eg, motor and cognitive impairment) in isolated rapid eye movement sleep behavior disorder (iRBD) are associated with faster phenoconversion, their longitudinal trajectory patterns (linear or nonlinear) remain unclear. Additionally, evidence regarding the magnitude of neurodegenerative risk in iRBD compared to non-RBD individuals remains limited.
objectivesThe aim was to investigate longitudinal changes in clinical markers and assess the magnitude of neurodegenerative risk in iRBD versus non-RBD subjects.
methodsIn this prospective matched cohort study, video-polysomnography-confirmed iRBD patients and age- and sex-matched non-RBD subjects were followed every 1.5-2 years to evaluate neurodegenerative outcomes and markers. Longitudinal marker changes and neurodegenerative risk between groups were compared.
resultsOne-hundred thirty-three iRBD patients and 101 non-RBD subjects were followed for a mean of 6.9 ± 2.9 years. Parkinsonism-first converters were associated with motor dysfunction, whereas dementia-first converters were associated with cognitive, motor, olfactory, and color vision dysfunctions. Motor and global cognitive functions exhibited nonlinear progression in iRBD, with marked acceleration before parkinsonism or dementia diagnosis. Conversion rates in iRBD patients were 4.7% at 3 years, 30.1% at 7 years, and 79.5% at 13 years, exceeding those in non-RBD subjects (3% at 3 years and 16.1% at 13 years). iRBD patients had a higher neurodegeneration risk (hazard ratio [95% confidence interval [CI]: 9.6 [3.8, 23.8], P < 0.001).
conclusionsMotor and global cognition demonstrate nonlinear accelerating progressions during iRBD phenoconversion. iRBD carries a nearly 10-fold higher risk of future neurodegeneration than non-RBD subjects. These findings highlighted a critical window for risk stratification and early intervention before neurodegenerative disease onset in iRBD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.